title: Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction.
abstract: OBJECTIVE
  To elucidate whether prognosis after acute myocardial infarction can be predicted by measuring plasma adrenomedullin, a novel vasorelaxant peptide.
  
  
  METHODS
  Plasma adrenomedullin concentrations on day 2 after myocardial infarction were measured in 113 patients with myocardial infarction with other clinical and haemodynamic variables related to mortality.
  
  
  RESULTS
  During a mean follow up period of 25 months, 16 patients died of cardiac causes. Plasma adrenomedullin concentrations on day 2 increased significantly in patients with myocardial infarction compared with controls (mean (SD), 12.3 (8.8) v 4.9 (1.0) pmol/l, p < 0.001). Plasma adrenomedullin correlated negatively with left ventricular ejection fraction on admission (r = -0.47, p < 0.001), although it did not significantly correlate with any other haemodynamic variable. By univariate Cox proportional hazards analysis, plasma adrenomedullin, age, coronary reperfusion, maximum creatine kinase concentrations, pulmonary congestion, pulmonary capillary wedge pressure, cardiac index, and left ventricular ejection fraction were all significantly related to mortality. Among the non-invasive variables, only plasma adrenomedullin was an independent predictor of mortality after myocardial infarction (p < 0.05). The Kaplan-Meier survival curves based on the median plasma adrenomedullin concentration (10.3 pmol/l) showed that patients with high plasma adrenomedullin had a higher mortality than those with low plasma adrenomedullin (p < 0.01).
  
  
  CONCLUSIONS
  Plasma adrenomedullin on day 2 after myocardial infarction is strongly associated with long term mortality, and thus may complement standard prognostic indicators.
authors.affiliation: Department of Internal Medicine, National Cardiovascular Centre, 5-7-1 Fujishirodai, Suita, Osaka 565, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Nagaya
authors.forename: T
authors.initials: T
authors.lastname: Nishikimi
authors.forename: M
authors.initials: M
authors.lastname: Uematsu
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshitomi
authors.forename: Y
authors.initials: Y
authors.lastname: Miyao
authors.forename: S
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Goto
authors.forename: S
authors.initials: S
authors.lastname: Kojima
authors.forename: M
authors.initials: M
authors.lastname: Kuramochi
authors.forename: H
authors.initials: H
authors.lastname: Matsuo
authors.forename: K
authors.initials: K
authors.lastname: Kangawa
authors.forename: H
authors.initials: H
authors.lastname: Nonogi
mesh_terms: D053607:Adrenomedullin; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D015415:Biomarkers; D010455:Peptides; D053607:Adrenomedullin